Previous close | 62.34 |
Open | 62.47 |
Bid | 62.16 x 0 |
Ask | 62.27 x 0 |
Day's range | 62.23 - 62.47 |
52-week range | 59.81 - 79.86 |
Volume | |
Avg. volume | 11 |
Market cap | 77.635B |
Beta (5Y monthly) | 0.23 |
PE ratio (TTM) | 188.58 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (4.63%) |
Ex-dividend date | 14 Jun 2024 |
1y target est | N/A |
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)